There may be as yet undiscovered circumstances where NF-κB inhibitors can be considered in combination with docetaxel to reduce tumor invasion or in combination with HDAC inhibitors to reduce tumor growth, but this does not appear to be a combination therapy that could be broadly applied to patients with advanced thyroid cancer. This evidence concerns the gene NFKB1 and thyroid gland carcinoma.